Ontak and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Ontak (denileukin diftitox), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Compazine, and have Eczema.

The phase IV clinical study analyzes which people have Weakness when taking Ontak. It is created by eHealthMe based on reports of 456 people who have side effects when taking Ontak from the FDA, and is updated regularly.

What is Ontak?

Ontak has active ingredients of denileukin diftitox. eHealthMe is studying from 457 Ontak users. Check the latest studies of Ontak.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,613 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 23, 2026

456 people reported to have side effects when taking Ontak.
Among them, 37 people (8.11%) have Weakness.

Among these 37 people:

How long have people been on Ontak when they have Weakness? *

What is the gender of people who have Weakness when taking Ontak? *

female: 44.44 %
male: 55.56 %

What is the age of people who have Weakness when taking Ontak? *

What are other drugs people take besides Ontak? *

What are other side effects people have besides Weakness? *

Dyspnea (difficult or laboured breathing): 13 people, 35.14%
Pain: 10 people, 27.03%
Fatigue (feeling of tiredness): 9 people, 24.32%
Nausea (feeling of having an urge to vomit): 8 people, 21.62%
Blood Albumin Decreased: 8 people, 21.62%
Rashes (redness): 8 people, 21.62%
Fever: 7 people, 18.92%
Confusional State: 6 people, 16.22%
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight): 6 people, 16.22%
Oedema Peripheral (superficial swelling): 6 people, 16.22%

What are the existing conditions these people have? *

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 5 people, 13.51%
Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 4 people, 10.81%
Non-Small Cell Lung Cancer Stage Iv: 2 people, 5.41%
Ovarian Cancer (cancer of ovary): 1 person, 2.70%
Mycosis Fungoides (lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin): 1 person, 2.70%
Lymphoma (cancer that begins in immune system cells): 1 person, 2.70%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 2.70%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 2.70%
High Blood Pressure: 1 person, 2.70%
High Blood Cholesterol: 1 person, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Ontak and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ontak:

Ontak (457 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Ontak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,613 conditions)

Related publications that referenced our studies

Tridente G, "Denileukin-Diftitox", InAdverse Events with Biomedicines, 2014 Jan .
Tridente G, "Denileukin-Diftitox", InAdverse Events with Biomedicines, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on denileukin diftitox (the active ingredients of Ontak) and Ontak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.